Published in AIDS Behav on July 01, 2013
Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men | NCT00458393
A Multilevel Gaming Intervention for Persons on PrEP | NCT02611362
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A (2013) 1.50
Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis (2014) 1.36
FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2014) 1.36
Preventing HIV among young people: research priorities for the future. J Acquir Immune Defic Syndr (2013) 1.05
Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. AIDS Behav (2015) 1.03
Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm (2013) 1.02
Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. AIDS Patient Care STDS (2014) 1.02
Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial. AIDS Behav (2014) 1.00
Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS (2016) 0.99
Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob Agents Chemother (2015) 0.99
Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial. AIDS Behav (2015) 0.98
Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation. AIDS Patient Care STDS (2014) 0.97
Sustained High HIV Incidence in Young Women in Southern Africa: Social, Behavioral, and Structural Factors and Emerging Intervention Approaches. Curr HIV/AIDS Rep (2015) 0.97
Disclosure of pharmacokinetic drug results to understand nonadherence. AIDS (2015) 0.96
Facilitators of adherence to the study pill in the FEM-PrEP clinical trial. PLoS One (2015) 0.94
Tailored combination prevention packages and PrEP for young key populations. J Int AIDS Soc (2015) 0.93
Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. Antimicrob Agents Chemother (2014) 0.93
Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions. HIV Med (2014) 0.91
An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings. J Int AIDS Soc (2014) 0.90
Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Antimicrob Agents Chemother (2014) 0.89
Global HIV epidemiology: A guide for strategies in prevention and care. Curr HIV/AIDS Rep (2014) 0.85
Adherence and the Lie in a HIV Prevention Clinical Trial. Med Anthropol (2015) 0.85
An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate. Int J Pharm (2015) 0.84
Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. Retrovirology (2013) 0.84
Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya. AIDS Behav (2015) 0.83
Lay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study. AIDS Behav (2015) 0.83
Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study. AIDS Behav (2014) 0.83
The promise and peril of pre-exposure prophylaxis (PrEP): using social science to inform prep interventions among female sex workers. Afr J Reprod Health (2014) 0.82
Optimizing adherence to preexposure and postexposure prophylaxis: the need for an integrated biobehavioral approach. Clin Infect Dis (2015) 0.81
Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses. J Acquir Immune Defic Syndr (2015) 0.80
Passing the baton: Community-based ethnography to design a randomized clinical trial on the effectiveness of oral pre-exposure prophylaxis for HIV prevention among Black men who have sex with men. Contemp Clin Trials (2015) 0.78
Ending the pandemic: reducing new HIV infections to zero. J Int AIDS Soc (2013) 0.76
A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis. Pharm Res (2016) 0.76
Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care. J Gen Intern Med (2016) 0.75
Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. Antimicrob Agents Chemother (2016) 0.75
An intravaginal ring for real-time evaluation of adherence to therapy. PLoS One (2017) 0.75
HIV prevention and research considerations for women in sub-Saharan Africa: moving toward biobehavioral prevention strategies. Afr J Reprod Health (2014) 0.75
Parenting Among Adolescents and Young Adults with Human Immunodeficiency Virus Infection in the United States: Challenges, Unmet Needs, and Opportunities. AIDS Patient Care STDS (2016) 0.75
Planning ahead for implementation of long-acting HIV prevention: challenges and opportunities. Curr Opin HIV AIDS (2015) 0.75
Sexual Relationships Outside Primary Partnerships and Abstinence Are Associated With Lower Adherence and Adherence Gaps: Data From the Partners PrEP Ancillary Adherence Study. J Acquir Immune Defic Syndr (2015) 0.75
Controlling the hydration rate of a hydrophilic matrix in the core of an intravaginal ring determines antiretroviral release. J Control Release (2015) 0.75
Delivering PrEP to pregnant and breastfeeding women in sub-Saharan africa: The implementation science frontier. AIDS (2017) 0.75
Plasma Tenofovir-levels to Support Adherence to TDF/FTC Pre-exposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. J Acquir Immune Defic Syndr (2017) 0.75
Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial. J Acquir Immune Defic Syndr (2017) 0.75
Experiences Using Pre-Exposure Prophylaxis for Safer Conception Among HIV Serodiscordant Heterosexual Couples in the United States. AIDS Patient Care STDS (2017) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Changing AIDS-risk behavior. Psychol Bull (1992) 14.87
Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet (2011) 5.34
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep (2011) 4.85
Motivational interviewing in health care settings. Opportunities and limitations. Am J Prev Med (2001) 4.70
What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr (2012) 3.44
Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep (2012) 2.95
Intervention mapping: protocol for applying health psychology theory to prevention programmes. J Health Psychol (2004) 2.89
Antiretroviral prophylaxis: a defining moment in HIV control. Lancet (2011) 2.17
A review of health behaviour theories: how useful are these for developing interventions to promote long-term medication adherence for TB and HIV/AIDS? BMC Public Health (2007) 2.11
Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep (2008) 2.09
The information-motivation-behavioral skills model of antiretroviral adherence and its applications. Curr HIV/AIDS Rep (2008) 1.83
Clinician-initiated HIV risk reduction intervention for HIV-positive persons: Formative Research, Acceptability, and Fidelity of the Options Project. J Acquir Immune Defic Syndr (2004) 1.80
Strategies to improve adherence and acceptability of hormonal methods of contraception. Cochrane Database Syst Rev (2011) 1.44
Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav (2012) 1.44
Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS (2012) 1.40
State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr (2012) 1.37
An agenda for advancing the science of implementation of evidence-based HIV prevention interventions. AIDS Behav (2009) 1.06
Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial. Contemp Clin Trials (2011) 1.04
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl J Med (2015) 3.64
Early age of first sex: a risk factor for HIV infection among women in Zimbabwe. AIDS (2004) 3.30
Biomarker validation of reports of recent sexual activity: results of a randomized controlled study in Zimbabwe. Am J Epidemiol (2009) 2.57
Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med (2011) 1.89
Hantavirus pulmonary syndrome--United States: updated recommendations for risk reduction. Centers for Disease Control and Prevention. MMWR Recomm Rep (2002) 1.77
Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav (2010) 1.60
Acceptability in microbicide and PrEP trials: current status and a reconceptualization. Curr Opin HIV AIDS (2012) 1.55
Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One (2010) 1.55
Continued high risk sexual behavior following diagnosis with acute HIV infection in South Africa and Malawi: implications for prevention. AIDS Behav (2011) 1.41
Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. J Acquir Immune Defic Syndr (2015) 1.32
Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS (2013) 1.25
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials (2011) 1.15
Consistent condom use in married Zimbabwean women after a condom intervention. Sex Transm Dis (2008) 1.13
A model for improving physician performance in developing countries: a three-year postgraduate training program in Laos. Acad Med (2006) 1.11
The importance of male partner involvement for women's acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe. AIDS Behav (2011) 1.10
Barrier method preferences and perceptions among Zimbabwean women and their partners. AIDS Behav (2005) 1.10
Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav (2014) 1.09
Acceptability and use of the diaphragm and Replens lubricant gel for HIV prevention in Southern Africa. AIDS Behav (2009) 1.08
Evaluating nurses' implementation of an infant-feeding counseling protocol for HIV-infected mothers: The Ban Study in Lilongwe, Malawi. AIDS Educ Prev (2009) 1.07
The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One (2008) 1.06
Predictors for mortality and loss to follow-up among children receiving anti-retroviral therapy in Lilongwe, Malawi. Trop Med Int Health (2009) 1.05
Analyzing Direct Effects in Randomized Trials with Secondary Interventions: An Application to HIV Prevention Trials. J R Stat Soc Ser A Stat Soc (2009) 1.03
Probiotics: potential to prevent HIV and sexually transmitted infections in women. Sex Transm Dis (2008) 1.03
Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm (2013) 1.02
The importance of discreet use of the diaphragm to Zimbabwean women and their partners. AIDS Behav (2006) 1.00
Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial. AIDS Behav (2015) 0.98
Degrees of disclosure: a study of women's covert use of the diaphragm in an HIV prevention trial in sub-Saharan Africa. Soc Sci Med (2009) 0.98
Introducing diaphragms into the mix: what happens to male condom use patterns? AIDS Behav (2005) 0.97
African women recently infected with HIV-1 and HSV-2 have increased risk of acquiring Neisseria gonorrhoeae and Chlamydia trachomatis in the Methods for Improving Reproductive Health in Africa trial. Sex Transm Dis (2011) 0.97
"Male involvement" in women and children's HIV prevention: challenges in definition and interpretation. J Acquir Immune Defic Syndr (2011) 0.97
User experiences and acceptability attributes of the diaphragm and lubricant gel in an HIV prevention trial in southern Africa. AIDS Care (2011) 0.95
Duet for menstrual protection: a feasibility study in Zimbabwe. Contraception (2009) 0.95
Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding". AIDS Behav (2015) 0.95
Sharing the trousers: gender roles and relationships in an HIV-prevention trial in Zimbabwe. Cult Health Sex (2012) 0.94
Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. Antivir Ther (2012) 0.94
Feasibility of a breath test for monitoring adherence to vaginal administration of antiretroviral microbicide gels. J Clin Pharmacol (2013) 0.93
Contraception use and effectiveness among women in a trial of the diaphragm for HIV prevention. Contraception (2011) 0.92
An acceptability and safety study of the Duet cervical barrier and gel delivery system in Zimbabwe. J Int AIDS Soc (2010) 0.92
A comparison of four condom-use measures in predicting pregnancy, cervical STI and HIV incidence among Zimbabwean women. Sex Transm Infect (2009) 0.90
"Come back when you're dying:" the commodification of AIDS among California's urban poor. Soc Sci Med (2002) 0.89
Female condom uptake and acceptability in Zimbabwe. AIDS Educ Prev (2008) 0.88
Influences on visit retention in clinical trials: insights from qualitative research during the VOICE trial in Johannesburg, South Africa. BMC Womens Health (2014) 0.87
The preventive misconception: experiences from CAPRISA 004. AIDS Behav (2014) 0.86
Intimate partner violence and condom and diaphragm nonadherence among women in an HIV prevention trial in southern Africa. J Acquir Immune Defic Syndr (2013) 0.86
Diaphragm and lubricant gel acceptance, skills and patterns of use among women in an effectiveness trial in Southern Africa. Eur J Contracept Reprod Health Care (2009) 0.85
The effect of the vaginal diaphragm and lubricant gel on acquisition of HSV-2. Sex Transm Infect (2011) 0.83
A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs (2012) 0.82
Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial. PLoS One (2013) 0.81
What the better half is thinking: A comparison of men's and women's responses and agreement between spouses regarding reported sexual and reproductive behaviors in Rwanda. Psychol Res Behav Manag (2009) 0.81
Impact of learning HIV status on contraceptive use in the MIRA trial. J Fam Plann Reprod Health Care (2011) 0.80
Perceptions of voluntary medical male circumcision among circumcising and non-circumcising communities in Malawi. Glob Public Health (2015) 0.79
A qualitative study of obstacles to diaphragm and condom use in an HIV prevention trial in sub-Saharan Africa. AIDS Educ Prev (2012) 0.79
Monitoring microbicide gel use with real-time notification of the container's opening events: results of the CAPRISA Wisebag study. AIDS Behav (2014) 0.79
Changes in sexual risk behavior before and after HIV seroconversion in Southern African women enrolled in a HIV prevention trial. J Acquir Immune Defic Syndr (2011) 0.78
Establishing a continuum of care between HIV prevention trials and public healthcare systems: the MIRA Standard of Care program. Clin Trials (2010) 0.78
Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS (2017) 0.78
Antiretroviral preexposure prophylaxis for HIV prevention. N Engl J Med (2013) 0.77
Measuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial. AIDS Behav (2014) 0.76
Diaphragm used with replens gel and risk of bacterial vaginosis: results from a randomized controlled trial. Infect Dis Obstet Gynecol (2012) 0.76
Genital-Systemic Chemokine Gradients and the Risk of HIV Acquisition in Women. J Acquir Immune Defic Syndr (2017) 0.75
Bridewealth and sexual and reproductive practices among women in Harare, Zimbabwe. AIDS Care (2010) 0.75
Partnerships between a University-Affiliated Clinic and Community Based Organizations to Reach Black Men who have Sex with Men for PrEP Care. J Acquir Immune Defic Syndr (2017) 0.75
Genital - Systemic chemokine gradients and the risk of HIV acquisition in women. J Acquir Immune Defic Syndr (2016) 0.75
"It's inside my body and it's mine". AIDS (2017) 0.75